Open Access
Article
"CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression"
Renato Franco1,Gerardo Botti1,Massimo Mascolo1,Giovanna Loquercio1,Giuseppina Liguori1,Gennaro Ilardi1,Simona Losito1,Anna La Mura1,Rosa Calemma1,Caterina Ierano1,Jane Bryce1,Crescenzo D'Alterio1,Stefania Scala1
1
Pathology Department, National Cancer Institute G Pascale, Naples, Italy. renfr@yahoo.com
DOI: 10.2741/E60 Volume 2 Issue 1, pp.13-21
Published: 01 January 2010
(This article belongs to the Special Issue Gene targets for modulating cell growth)
Abstract

Despite improvements in early diagnosis of uveal melanoma, prognosis is still poor due to metastases development. Neoangiogenesis and migration are requisites to metastasis promotion. Cross-talking between CXCR4-CXCL12 axis and the VEGF pathway was shown to favours tumour progression. CXCR4-CXCL12-VEGF expression was evaluated by immunohistochemistry in 53 selected cases of primary uveal melanoma and in liver melanoma metastases. CXCR4 protein was detected in 41.4 per cent cases, CXCL12 in 43.4 per cent cases and VEGF expression in 39.6 per cent cases. A significant correlation was found between CXCR4 and VEGF expression (p=0.011), CXCL12 and both tumour dimension and (p=0.006) and epithelioid-mixed cytotype (p=0.012). The two cases of uveal melanoma liver metastases in our series showed CXCR4 expression, weak immunoreactivity for CXCL12 and absent VEGF immunostaining. These data indicate that CXCR4-CXCL12 axis and its cross-talking with VEGF plays a role in uveal melanoma metastases and may be new prognostic markers in UMM. Moreover, these results suggest that targeted inhibition of CXCR4 could be introduced to control metastasis development in UMM.

Share and Cite
Renato Franco, Gerardo Botti, Massimo Mascolo, Giovanna Loquercio, Giuseppina Liguori, Gennaro Ilardi, Simona Losito, Anna La Mura, Rosa Calemma, Caterina Ierano, Jane Bryce, Crescenzo D'Alterio, Stefania Scala. "CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression". Frontiers in Bioscience-Elite. 2010. 2(1); 13-21.